Skip to main content
Top
Published in: Inflammation 5/2014

01-10-2014

Ginsenoside Metabolite Compound K Alleviates Adjuvant-Induced Arthritis by Suppressing T Cell Activation

Authors: Jingyu Chen, Huaxun Wu, Qingtong Wang, Yan Chang, Kangkang Liu, Shasha Song, Pingfan Yuan, Jingjing Fu, Wuyi Sun, Qiong Huang, Lihua Liu, Yujing Wu, Yunfang Zhang, Aiwu Zhou, Wei Wei

Published in: Inflammation | Issue 5/2014

Login to get access

Abstract

Ginsenoside metabolite compound K (CK) is the degradation product of ginsenosides in the intestine by bacteria and has many pharmacological activities including anti-inflammatory effects. Rheumatoid arthritis (RA) is an inflammatory and autoimmune disease characterized by chronic synovial inflammation and articular damage in multiple joints. However, the effect of CK on RA remains unclear. In this study, the effect of CK on adjuvant arthritis (AA) and the underlying mechanisms that focused on T cell activation were investigated. Complete Freund’s adjuvant was used to induce AA rats. After the onset of arthritis, rats were given CK (10, 40, and 160 mg/kg) or MTX (0.5 mg/kg). To evaluate the severity of arthritis, arthritis index and paw swelling were evaluated every 3 days. Histopathology of joint and spleen were assayed. Subsets of T cells including CD4 + CD62L+ (naïve T cells), CD4 + CD25+ (activated T cells), and CD4 + CD25 + Foxp3+ cells (Treg) and CD25 expression were assayed by flow cytometry. Proliferation of T cell was evaluated by 3H-TdR. IL-2 level was assayed by ELISA. We found that CK attenuated arthritis index and paw swelling, restored the histopathological change of joint and spleen, downregulated the percentage of activated T cells, and upregulated naïve T cells and Treg cells in spleen. CK significantly suppressed T cell activation (as indicated by T cell proliferation, CD25 expression, and IL-2 production). In conclusion, our results suggest that CK alleviates autoimmune arthritis by suppressing T cell activation.
Literature
1.
go back to reference Carmona, L., M. Cross, B. Williams, M. Lassere, and L. March. 2010. Rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology 24(6): 733–745.CrossRef Carmona, L., M. Cross, B. Williams, M. Lassere, and L. March. 2010. Rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology 24(6): 733–745.CrossRef
2.
go back to reference Rodeghero, R., Y. Cao, S.A. Olalekan, Y. Iwakua, T.T. Glant, and A. Finnegan. 2013. Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. Journal of Immunology 190(11): 5423–5435.CrossRef Rodeghero, R., Y. Cao, S.A. Olalekan, Y. Iwakua, T.T. Glant, and A. Finnegan. 2013. Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. Journal of Immunology 190(11): 5423–5435.CrossRef
3.
go back to reference Lundy, S.K., S. Sarkar, L.A. Tesmer, and D.A. Fox. 2007. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Research and Therapy 9(1): 202.PubMedCrossRefPubMedCentral Lundy, S.K., S. Sarkar, L.A. Tesmer, and D.A. Fox. 2007. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Research and Therapy 9(1): 202.PubMedCrossRefPubMedCentral
4.
go back to reference Rogers, J.L., D.S. Serafin, R.G. Timoshchenko, and T.K. Tarrant. 2012. Cellular targeting in autoimmunity. Current Allergy and Asthma Reports 12(6): 495–510.PubMedCrossRefPubMedCentral Rogers, J.L., D.S. Serafin, R.G. Timoshchenko, and T.K. Tarrant. 2012. Cellular targeting in autoimmunity. Current Allergy and Asthma Reports 12(6): 495–510.PubMedCrossRefPubMedCentral
5.
go back to reference Martin, R. 2012. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clinical Immunology 142(1): 9–14.PubMedCrossRef Martin, R. 2012. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clinical Immunology 142(1): 9–14.PubMedCrossRef
6.
go back to reference Chang, Y., Y. Wu, D. Wang, W. Wei, Q. Qin, G. Xie, L. Zhang, S. Yan, J. Chen, Q. Wang, H. Wu, F. Xiao, W. Sun, J. Jin, and W. Wang. 2011. Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. Rheumatology (Oxford) 50(5): 862–870.CrossRef Chang, Y., Y. Wu, D. Wang, W. Wei, Q. Qin, G. Xie, L. Zhang, S. Yan, J. Chen, Q. Wang, H. Wu, F. Xiao, W. Sun, J. Jin, and W. Wang. 2011. Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. Rheumatology (Oxford) 50(5): 862–870.CrossRef
7.
go back to reference Song, S.S., B. Huang, Q.T. Wang, Y.J. Wu, J.J. Fu, Y.F. Zhang, Y. Chang, J.Y. Chen, H.X. Wu, D. Wang, L.L. Zhang, and W. Wei. 2013. BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats. Acta Pharmacologica Sinica 34(3): 414–423.PubMedCrossRefPubMedCentral Song, S.S., B. Huang, Q.T. Wang, Y.J. Wu, J.J. Fu, Y.F. Zhang, Y. Chang, J.Y. Chen, H.X. Wu, D. Wang, L.L. Zhang, and W. Wei. 2013. BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats. Acta Pharmacologica Sinica 34(3): 414–423.PubMedCrossRefPubMedCentral
8.
go back to reference Chi, H., and G.E. Ji. 2005. Transformation of ginsenosides Rb1 and Re from Panax ginseng by food microorganisms. Biotechnological Letters 27(11): 765–771.CrossRef Chi, H., and G.E. Ji. 2005. Transformation of ginsenosides Rb1 and Re from Panax ginseng by food microorganisms. Biotechnological Letters 27(11): 765–771.CrossRef
9.
go back to reference Tawab, M.A., U. Bahr, M. Karas, M. Wurglics, and M. Schubert-Zsilavecz. 2003. Degradation of ginsenosides in humans after oral administration. Drug Metabolism and Disposition 31(8): 1065–1071.PubMedCrossRef Tawab, M.A., U. Bahr, M. Karas, M. Wurglics, and M. Schubert-Zsilavecz. 2003. Degradation of ginsenosides in humans after oral administration. Drug Metabolism and Disposition 31(8): 1065–1071.PubMedCrossRef
10.
go back to reference Joh, E.H., I.A. Lee, I.H. Jung, and D.H. Kim. 2011. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation. Biochemical Pharmacology 82(3): 278–286.PubMedCrossRef Joh, E.H., I.A. Lee, I.H. Jung, and D.H. Kim. 2011. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation. Biochemical Pharmacology 82(3): 278–286.PubMedCrossRef
11.
go back to reference Park, E.K., Y.W. Shin, H.U. Lee, S.S. Kim, Y.C. Lee, B.Y. Lee, and D.H. Kim. 2005. Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced by lipopolysaccharide. Biological and Pharmaceutical Bulletin 28(4): 652–656.PubMedCrossRef Park, E.K., Y.W. Shin, H.U. Lee, S.S. Kim, Y.C. Lee, B.Y. Lee, and D.H. Kim. 2005. Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced by lipopolysaccharide. Biological and Pharmaceutical Bulletin 28(4): 652–656.PubMedCrossRef
12.
go back to reference Yang, C.S., S.R. Ko, B.G. Cho, D.M. Shin, J.M. Yuk, S. Li, J.M. Kim, R.M. Evans, J.S. Jung, D.K. Song, and E.K. Jo. 2008. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. Journal of Cellular and Molecular Medicine 12(5A): 1739–1753.PubMedCrossRef Yang, C.S., S.R. Ko, B.G. Cho, D.M. Shin, J.M. Yuk, S. Li, J.M. Kim, R.M. Evans, J.S. Jung, D.K. Song, and E.K. Jo. 2008. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. Journal of Cellular and Molecular Medicine 12(5A): 1739–1753.PubMedCrossRef
13.
go back to reference Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344(12): 907–916.PubMedCrossRef Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344(12): 907–916.PubMedCrossRef
14.
go back to reference Létourneau, S., C. Krieg, G. Pantaleo, and O. Boyman. 2009. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. Journal of Allergy and Clinical Immunology 123(4): 758–762.PubMedCrossRef Létourneau, S., C. Krieg, G. Pantaleo, and O. Boyman. 2009. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. Journal of Allergy and Clinical Immunology 123(4): 758–762.PubMedCrossRef
15.
go back to reference Laurence, A., C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, and J.J. O'shea. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3): 371–381.PubMedCrossRef Laurence, A., C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, and J.J. O'shea. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3): 371–381.PubMedCrossRef
16.
go back to reference Cote-Sierra, J., G. Foucras, L. Guo, L. Chiodetti, H.A. Young, J. Hu-Li, J. Zhu, and W.E. Paul. 2004. Interleukin 2 plays a central role in Th2 differentiation. Proceedings of the National Academy of Sciences of the United States of America 101(11): 3880–3885.PubMedCrossRefPubMedCentral Cote-Sierra, J., G. Foucras, L. Guo, L. Chiodetti, H.A. Young, J. Hu-Li, J. Zhu, and W.E. Paul. 2004. Interleukin 2 plays a central role in Th2 differentiation. Proceedings of the National Academy of Sciences of the United States of America 101(11): 3880–3885.PubMedCrossRefPubMedCentral
17.
go back to reference Kovanen, P.E., and W.J. Leonard. 2004. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunological Reviews 202: 67–83.PubMedCrossRef Kovanen, P.E., and W.J. Leonard. 2004. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunological Reviews 202: 67–83.PubMedCrossRef
18.
go back to reference Dooms, H., E. Kahn, B. Knoechel, and A.K. Abbas. 2004. IL-2 induces a competitive survival advantage in T lymphocytes. Journal of Immunology 172(10): 5973–5979.CrossRef Dooms, H., E. Kahn, B. Knoechel, and A.K. Abbas. 2004. IL-2 induces a competitive survival advantage in T lymphocytes. Journal of Immunology 172(10): 5973–5979.CrossRef
19.
go back to reference Dooms, H., K. Wolslegel, P. Lin, and A.K. Abbas. 2007. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. Journal of Experimental Medicine 204(3): 547–557.PubMedCrossRefPubMedCentral Dooms, H., K. Wolslegel, P. Lin, and A.K. Abbas. 2007. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. Journal of Experimental Medicine 204(3): 547–557.PubMedCrossRefPubMedCentral
20.
go back to reference Brok, H.P., J.M. Tekoppele, J. Hakimi, J.A. Kerwin, E.M. Nijenhuis, C.W. De Groot, R.E. Bontrop, and B.A. ‘t Hart. 2001. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clinical and Experimental Immunology 124(1): 134–141.PubMedCrossRefPubMedCentral Brok, H.P., J.M. Tekoppele, J. Hakimi, J.A. Kerwin, E.M. Nijenhuis, C.W. De Groot, R.E. Bontrop, and B.A. ‘t Hart. 2001. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clinical and Experimental Immunology 124(1): 134–141.PubMedCrossRefPubMedCentral
21.
go back to reference Mijnheer, G., B.J. Prakken, and F. van Wijk. 2013. The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics. Current Opinion in Rheumatology 25(2): 260–267.PubMedCrossRef Mijnheer, G., B.J. Prakken, and F. van Wijk. 2013. The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics. Current Opinion in Rheumatology 25(2): 260–267.PubMedCrossRef
22.
go back to reference Ehrenstein, M.R., J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. Journal of Experimental Medicine 200(3): 277–285.PubMedCrossRefPubMedCentral Ehrenstein, M.R., J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. Journal of Experimental Medicine 200(3): 277–285.PubMedCrossRefPubMedCentral
23.
go back to reference Buckner, J.H. 2010. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nature Reviews Immunology 10: 849–859.PubMedCrossRefPubMedCentral Buckner, J.H. 2010. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nature Reviews Immunology 10: 849–859.PubMedCrossRefPubMedCentral
24.
go back to reference Frey, O., P.K. Petrow, M. Gajda, K. Siegmund, J. Huehn, A. Scheffold, A. Hamann, A. Radbruch, and R. Bräuer. 2005. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Research and Therapy 7(2): R291–R301.PubMedCrossRefPubMedCentral Frey, O., P.K. Petrow, M. Gajda, K. Siegmund, J. Huehn, A. Scheffold, A. Hamann, A. Radbruch, and R. Bräuer. 2005. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Research and Therapy 7(2): R291–R301.PubMedCrossRefPubMedCentral
25.
go back to reference Kong, N., Q. Lan, M. Chen, T. Zheng, W. Su, J. Wang, Z. Yang, R. Park, G. Dagliyan, P.S. Conti, D. Brand, Z. Liu, H. Zou, W. Stohl, and S.G. Zheng. 2012. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Annals of the Rheumatic Diseases 71(9): 1567–1572.PubMedCrossRefPubMedCentral Kong, N., Q. Lan, M. Chen, T. Zheng, W. Su, J. Wang, Z. Yang, R. Park, G. Dagliyan, P.S. Conti, D. Brand, Z. Liu, H. Zou, W. Stohl, and S.G. Zheng. 2012. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Annals of the Rheumatic Diseases 71(9): 1567–1572.PubMedCrossRefPubMedCentral
26.
go back to reference Shevach, E.M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30(5): 636–645.PubMedCrossRef Shevach, E.M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30(5): 636–645.PubMedCrossRef
27.
go back to reference Wing, K., Z. Fehérvári, S. Sakaguchi, K. Wing, Z. Fehervari, and S. Sakaguchi. 2006. Emerging possibilities in the development and function of regulatory T cells. International Immunology 18(7): 991–1000.PubMedCrossRef Wing, K., Z. Fehérvári, S. Sakaguchi, K. Wing, Z. Fehervari, and S. Sakaguchi. 2006. Emerging possibilities in the development and function of regulatory T cells. International Immunology 18(7): 991–1000.PubMedCrossRef
28.
go back to reference Wu, H., J. Chen, Q. Wang, X. Jia, S. Song, P. Yuan, K. Liu, L. Liu, Y. Zhang, A. Zhou, and W. Wei. 2014. Ginsenoside metabolite compound K attenuates inflammatory responses of adjuvant-induced arthritis rats. Immunopharmacology and Immunotoxicology Wu, H., J. Chen, Q. Wang, X. Jia, S. Song, P. Yuan, K. Liu, L. Liu, Y. Zhang, A. Zhou, and W. Wei. 2014. Ginsenoside metabolite compound K attenuates inflammatory responses of adjuvant-induced arthritis rats. Immunopharmacology and Immunotoxicology
Metadata
Title
Ginsenoside Metabolite Compound K Alleviates Adjuvant-Induced Arthritis by Suppressing T Cell Activation
Authors
Jingyu Chen
Huaxun Wu
Qingtong Wang
Yan Chang
Kangkang Liu
Shasha Song
Pingfan Yuan
Jingjing Fu
Wuyi Sun
Qiong Huang
Lihua Liu
Yujing Wu
Yunfang Zhang
Aiwu Zhou
Wei Wei
Publication date
01-10-2014
Publisher
Springer US
Published in
Inflammation / Issue 5/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9887-0

Other articles of this Issue 5/2014

Inflammation 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine